Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. - Gordon,A.N.; Tonda,M.; Sun,S.; Rackoff,W. (Gynecol Oncol, 2004)